NCT03710603 · OUTCOME

Overall Survival (OS)

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma · Source last updated 2026-02-10

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From randomization to the clinical cutoff date. Maximum follow up was 54.41 months

What was measured

Overall Survival (OS), measured from the date of from randomization to the date the subject's death

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Overall Survival (OS), measured from the date of from randomization to the date the subject's death
reporting Status: NOT_POSTED
time Frame: From randomization to the clinical cutoff date. Maximum follow up was 54.41 months
title: Overall Survival (OS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice